[go: up one dir, main page]

AU2039800A - 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins - Google Patents

5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins

Info

Publication number
AU2039800A
AU2039800A AU20398/00A AU2039800A AU2039800A AU 2039800 A AU2039800 A AU 2039800A AU 20398/00 A AU20398/00 A AU 20398/00A AU 2039800 A AU2039800 A AU 2039800A AU 2039800 A AU2039800 A AU 2039800A
Authority
AU
Australia
Prior art keywords
modulatorsof
selectins
treatment
human diseases
diseases involving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20398/00A
Inventor
Jei-Fei Cheng
Todd Kevin Jones
Adnan M. M. Mjalli
Truc Ngoc Nguyen
Raj Kumar Raheja
William Charles Ripka
Deborah Helen Slee
Jinghua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontogen Corp
Original Assignee
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontogen Corp filed Critical Ontogen Corp
Publication of AU2039800A publication Critical patent/AU2039800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU20398/00A 1998-12-04 1999-12-03 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins Abandoned AU2039800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11102698P 1998-12-04 1998-12-04
US11102598P 1998-12-04 1998-12-04
US60111025 1998-12-04
US60111026 1998-12-04
PCT/US1999/028692 WO2000033836A1 (en) 1998-12-04 1999-12-03 5-membered heterocycles for the treatment of human diseases involving modulators of selectins

Publications (1)

Publication Number Publication Date
AU2039800A true AU2039800A (en) 2000-06-26

Family

ID=26808588

Family Applications (2)

Application Number Title Priority Date Filing Date
AU20398/00A Abandoned AU2039800A (en) 1998-12-04 1999-12-03 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU21643/00A Abandoned AU2164300A (en) 1998-12-04 1999-12-03 Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU21643/00A Abandoned AU2164300A (en) 1998-12-04 1999-12-03 Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin

Country Status (2)

Country Link
AU (2) AU2039800A (en)
WO (2) WO2000034255A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244474T3 (en) 1999-09-29 2005-12-16 Ortho-Mcneil Pharmaceutical, Inc. ISONIPECOTAMIDE FOR THE TREATMENT OF DISORDERS MEDIATED BY INTEGRINE.
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003059880A1 (en) 2002-01-11 2003-07-24 Sankyo Company, Limited Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these
CN101870691A (en) 2002-08-19 2010-10-27 劳洛斯治疗公司 2,4,5-Trisubstituted imidazoles and their use as antibacterial agents
ATE546456T1 (en) 2003-05-30 2012-03-15 Gemin X Pharmaceuticals Canada Inc TRIHETEROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CANCER
JP5095216B2 (en) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド Arylimidazoles and their use as anticancer agents
US20050148601A1 (en) * 2003-12-19 2005-07-07 Maynard George D. Neurokinin-3 receptor modulators: diaryl imidazole derivatives
EP1711486B1 (en) 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobial agents
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
EP1577289A1 (en) 2004-03-18 2005-09-21 Revotar Biopharmaceuticals AG Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treament of inflammatory disorders
ES2473597T3 (en) 2005-05-25 2014-07-07 Lorus Therapeutics Inc. Derivatives of 2-indolyl imidazo [4,5-d] phenanthroline and its use in cancer treatment
EP1764093A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel aromatic compounds and their use in medical applications
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
EP1764096A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel phloroglucinol derivatives having selectin ligand activity
JP2010501567A (en) 2006-08-24 2010-01-21 ノバルティス アクチエンゲゼルシャフト 2- (pyrazin-2-yl) -thiazole and 2- (1H-pyrazole-3-) as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders Yl) thiazole derivatives and related compounds
EP2066664A1 (en) 2006-09-22 2009-06-10 Novartis AG Heterocyclic organic compounds
CN101595105B (en) 2006-12-20 2013-01-23 诺瓦提斯公司 2-substituted 5-membered heterocycles as SCD inhibitors
CA2739488A1 (en) 2008-10-15 2010-04-22 Boehringer Ingelheim International Gmbh Fused heteroaryl diamide compounds useful as mmp-13 inhibitors
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
AU2010221650B2 (en) * 2009-03-04 2015-06-25 Merck Sharp & Dohme Corp. Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents
WO2011005660A1 (en) 2009-07-08 2011-01-13 Valocor Therapeutics, Inc. Tofa analogs useful in treating dermatological disorders or conditions
CN107007597A (en) 2012-05-31 2017-08-04 菲尼克斯药品股份公司 It is used as the thiazole of orphan nuclear receptor ROR γ instrumentalities through formamide or sulfonamide substitutions and the pharmaceutical applications of related derivatives
CA2903866A1 (en) 2013-03-20 2014-09-25 Aptose Biosciences Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
KR20160058960A (en) 2013-10-04 2016-05-25 압토스 바이오사이언시스 인코포레이티드 Compositions and methods for treating cancers
AU2018360477A1 (en) 2017-10-30 2020-06-04 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN114105881B (en) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3002989A1 (en) * 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt HYDROXYPHENYL-THIAZOLE, -THIAZOLINE AND -THIAZOLIDINE-CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR INFLUENCING COLLAGEN METABOLISM
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units

Also Published As

Publication number Publication date
WO2000033836A9 (en) 2001-10-04
AU2164300A (en) 2000-06-26
WO2000034255A1 (en) 2000-06-15
WO2000033836A1 (en) 2000-06-15
WO2000034255A9 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
AU2039800A (en) 5-membered heterocycles for the treatment of human diseases involving modulatorsof selectins
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU3167499A (en) Human body cleaner
HUP0104963A3 (en) Compositions for the treatment of skin diseases
EP1144639A3 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
AU3596199A (en) Treatment of celiac disease
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU3784999A (en) Methods for treatment of pain
IL129144A0 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
AU3896900A (en) Treatment of pain
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
AU2021601A (en) Composition for the treatment of dandruff
AU3434601A (en) Compositions and methods for the treatment of immune related diseases
AU3760900A (en) Treatment of menstrual function
AU2566201A (en) Compounds and methods for the treatment of pain
IL135994A0 (en) Combination therapy for the treatment of aids
AU6288698A (en) Apparatus for stimulating the human body
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU1405001A (en) Treatment of diseases
AU3632899A (en) Method for the therapeutic and prophylactic treatment of dental diseases
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
AU3212099A (en) Method for increasing the permeability of horny human tissue
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase